hVIVO plc (LON:HVO - Get Free Report) shares traded down 46.3% during trading on Saturday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares changed hands during mid-day trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).
Analysts Set New Price Targets
Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a research report on Friday, May 30th.
View Our Latest Analysis on HVO
hVIVO Stock Performance
The stock has a fifty day simple moving average of GBX 15.98 and a two-hundred day simple moving average of GBX 17.81. The stock has a market cap of £73.38 million, a price-to-earnings ratio of 4.28 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61.
hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Analysts expect that hVIVO plc will post 1.5492958 EPS for the current fiscal year.
Insider Activity at hVIVO
In related news, insider Yamin Mo' Khan sold 3,062,246 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($703,774.26). 14.03% of the stock is currently owned by company insiders.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
